Business expansion through collaboration with Immuno-Biological Laboratories, CURED and others
First written in FY2016. 6 of 9 entries say "Restated". Latest entry: FY2019.
The whole theme swung hardest in 2022: 1 of 7 companies on the "Worse" side.
1 other company's latest entry also says "Restated".
- FY2019RestatedAnnual report
「In addition, we will strengthen our collaborative relationship with 株式会社免疫生物研究所, our capital and business alliance partner, and seek to create synergies with our group’s CRO business.」
We continue to pursue stronger collaboration with 免疫生物研究所 and the creation of synergies with the CRO business. - FY2018-Q3RestatedAnnual report
「In addition, we entered into a joint research and development agreement with 株式会社免疫生物研究所, our capital and business alliance partner, to develop an Alzheimer’s disease treatment through preclinical testing using the APPOSK mice described above and antibodies owned by the company.」
The joint research and development agreement with 免疫生物研究所 and efforts to develop an Alzheimer’s disease treatment using APPOSK mice are reiterated. - FY2018-Q2RestatedAnnual report
「In addition, we entered into a joint research and development agreement with ㈱免疫生物研究所, our capital and business alliance partner, to develop an Alzheimer’s disease treatment through preclinical testing using the APPOSK mice described above and antibodies owned by the company.」
The joint research and development agreement with 免疫生物研究所 and efforts to develop an Alzheimer’s disease treatment using APPOSK mice are reiterated. - FY2018-Q1AdvancedAnnual report
「In addition, we entered into a joint research and development agreement with ㈱免疫生物研究所, our capital and business alliance partner, to develop an Alzheimer’s disease treatment through preclinical testing using the APPOSK mice described above and antibodies owned by the company.」
We entered into a joint research and development agreement with 免疫生物研究所 to develop an Alzheimer’s disease treatment through the use of APPOSK mice. - FY2017RestatedAnnual report
「In addition, we will strengthen our collaborative relationship with ㈱免疫生物研究所, our capital and business alliance partner, and seek to create synergies with the genomics and CRO businesses of our group.」
We have reiterated our policy of strengthening collaboration with 免疫生物研究所 and seeking synergies with the genomics and CRO businesses. - FY2017-Q3RestatedAnnual report
「As part of its initiatives in new businesses, on 20 April of the previous year the Company resolved to, and did, subscribe jointly with its capital and business alliance partner 株式会社免疫生物研究所 for a third-party allotment of new shares conducted by that company, with a payment date of 11 May, in order to promote the practical application as an antibody drug of the anti-HIV antibody owned by ㈱CURED (Yokohama; research and development of antibody drugs).」
The joint investment in CURED with 免疫生物研究所 and efforts to commercialize anti-HIV antibodies are reiterated. - FY2017-Q2RestatedAnnual report
「As part of its initiatives in new businesses, on 20 April of the current year the Company resolved to, and did, subscribe jointly with its capital and business alliance partner 株式会社免疫生物研究所 for a third-party allotment of new shares conducted by that company, with a payment date of 11 May, in order to promote the practical application as an antibody drug of the anti-HIV antibody owned by ㈱CURED (Yokohama; research and development of antibody drugs).」
The joint investment in CURED with 免疫生物研究所 and efforts to commercialize anti-HIV antibodies are reiterated. - FY2017-Q1AdvancedAnnual report
「As part of its initiatives in new businesses, on 20 April of the current year the Company resolved to, and did, subscribe jointly with its capital and business alliance partner 株式会社免疫生物研究所 for a third-party allotment of new shares conducted by that company, with a payment date of 11 May, in order to promote the practical application as an antibody drug of the anti-HIV antibody owned by ㈱CURED (Yokohama; research and development of antibody drugs).」
Together with 免疫生物研究所, we subscribed to CURED’s third-party allotment and advanced the practical application of anti-HIV antibodies as an antibody drug. - FY2016First statedAnnual report
「In May of this year, we jointly invested with ㈱免疫生物研究所, our capital and business alliance partner, in ㈱CURED, a biotechnology venture specializing in the research and development of antibody drugs.」
We jointly invested in CURED with 免疫生物研究所 and are advancing expansion into the research and development of antibody drugs.